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Abstract
Severe pulmonary infection is a major threat to human health
accompanied by substantial medical costs, prolonged inpatient
requirements, and high mortality rates. New antimicrobial thera-
peutic strategies are urgently required to address the emergence
of antibiotic resistance and persistent bacterial infections. In this
study, we show that the constitutive expression of a native antimi-
crobial peptide LL-37 in transgenic mice aids in clearing Pseu-
domonas aeruginosa (PAO1), a major pathogen of clinical
pulmonary infection. Orthotopic transplantation of adult mouse
distal airway stem cells (DASCs), genetically engineered to express
LL-37, into injured mouse lung foci enabled large-scale incorpora-
tion of cells and long-term release of the host defense peptide,
protecting the mice from bacterial pneumonia and hypoxemia.
Further, correlates of DASCs in adult humans were isolated,
expanded, and genetically engineered to demonstrate successful
construction of an anti-infective artificial lung. Together, our stem
cell-based gene delivery therapeutic platform proposes a new
strategy for addressing recurrent pulmonary infections with future
translational opportunities.
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Introduction
Respiratory infection is amongst the leading causes of human death.
These include lower respiratory tract infections by Gram-negative
pathogens such as Pseudomonas aeruginosa which constitute the
main reason for hospital-associated infections and are associated
with high morbidity and mortality rates in hospitals. These continue
to pose a therapeutic challenge due to the rapid development of
resistance to standard antibiotic regimes during treatments. In the
case of the opportunistic pathogen P. aeruginosa, broad antibiotic
resistance has been observed, and 18–25% of clinical isolates
demonstrated multidrug resistance (Souli et al, 2008). Unfortu-
nately, relapse or re-infection is a frequent occurrence in patients
with pulmonary infections. To this end, the development of new
therapeutic strategies is needed to combat pulmonary bacterial
infections.
Antimicrobial peptides (AMPs) are substances produced by
animals, bacteria, and plants that are regarded as naturally occur-
ring broad-spectrum antibiotics. As an essential part of innate
immunity, AMPs possess the ability to kill invading pathogens
including bacteria, fungi, virus, and parasites (Zasloff, 2002; Fjell
et al, 2011; Kovach et al, 2012). The peptide hCAP-18/LL-37 (LL-
37) is the only human cathelicidin (CAMP) identified so far. The LL-
37 peptide is cleaved from hCAP-18 by proteinase, which enables it
to have a broad range of bactericidal activity against both Gram-
negative and Gram-positive organisms, including P. aeruginosa. LL-
37 has roles in multiple host defense processes by directly targeting
microbial biofilm and activating innate immune cell function (Scott
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et al, 2002; Overhage et al, 2008; Yu et al, 2010; Bandurska et al,
2015). In the inflamed human lung, LL-37 was reported to be highly
expressed and had potent anti-infective and anti-inflammatory
potential (Nijnik & Hancock, 2009; Currie et al, 2016), suggesting
that the LL-37 peptide can be used as an alternative medicine to
conventional antibiotics for treating pulmonary infection. However,
the degradation of the LL-37 peptide in vivo due to bacterial
proteases may limit its clinical application (Vandamme et al, 2012).
Furthermore, as a peptide with potential off-target toxicity, LL-37
requires topical delivery to infected foci, rather than systemically,
with local concentration control (Johansson et al, 1998; Heilborn
et al, 2005). Therefore, the development of a system to achieve local,
long-term LL-37 release may help combat pulmonary infection.
Viral systems have been utilized for exogenous gene expression;
however, clinical applicability for this approach has multiple draw-
backs including virus-induced tissue toxicity and inflammation post-
virus infection, oncogenic risks and genotoxicity, and the off-target
effects of the viral vector (i.e., liver). Here, we introduce a novel
platform combining conventional viral-based gene engineering with
intrapulmonary stem cell transplantation. We and others previously
demonstrated that distal airway stem cells (DASCs) derived from
p63+ lineage negative progenitors are the major regenerative cells
following large-scale lung damage (Kumar et al, 2011; Vaughan
et al, 2015; Zuo et al, 2015; Yang et al, 2018). DASCs have the
capacity to rapidly restore epithelial barriers in vivo and differentiate
into functional alveolar cells with accompanied Notch signaling
(Vaughan et al, 2015; Xi et al, 2017). The feasibility for large-scale
in vitro expansion and remarkable lung engraftment after transplan-
tation (Zuo et al, 2015; Imai-Matsushima et al, 2018) make DASCs
ideal candidates for cell therapy and gene engineering.
In the current study, via a novel transgenic rodent model, we
show that constitutive expression of human LL-37 peptide, in the
lung, enhances the pulmonary host defense system. Introduction of
LL-37 into mouse DASCs enable delivery of the antimicrobial
peptide specifically into injured foci without distribution to other
healthy lung regions, and endow the lung with enhanced bacterial
clearance ability. An anti-infective human bioengineered lung is also
constructed by engrafting LL-37-overexpressing human DASCs into
decellularized lung scaffolds. Taken together, we demonstrate that
genetically engineered DASCs can efficiently and specifically deliver
the antimicrobial peptide LL-37 in vivo and protect the lung against
pathogen infection.
Results
Constitutive LL-37 expression clears pulmonary infection in vivo
Clinical observations have indicated the elevation of LL-37 expres-
sion in lung disease exacerbation (Schaller-Bals et al, 2002; Pouwels
et al, 2015), suggesting that pulmonary infection and inflammation
could activate the LL-37-based protective mechanism. Here, to
understand whether the elevated expression of LL-37 in vivo is
beneficial, we constructed a novel transgenic mouse strain that
constitutively expressed the human hCAP-18 gene driven by the
EF1a promoter (Fig 1A). The expressed 18-kD hCAP-18 precursor
required additional processing to produce 4-kD LL-37 and acquired
biological functionality. To detect LL-37 expression, we collected
the lysate from wild-type FVB and LL-37 transgenic mice and
concentrated low-molecular-weight proteins by passing through a
10-kD centrifugal filter device. The expression of 4-kD LL-37, but
not larger proteins (i.e., GAPDH), was detected in the low-mole-
cular-weight ultrafiltrate in the transgenic mice (Fig 1B).
Bronchoalveolar lavage fluid (BALF) ultrafiltrate from LL-37
transgenic mice demonstrated a moderately enhanced bacteria inhi-
bitory function than wild-type FVB BALF when used to culture PAO1
in vitro. In contrast, high-molecular-weight retentates displayed little
difference in their bacterial inhibitory effect (Fig 1C). We also chal-
lenged mouse lung with equal amounts of PAO1 (5 × 106 CFU of
PAO1) and analyzed the lung homogenate at different time points
after infection. The results showed that the LL-37 transgenic mice
had significantly enhanced bacterial clearance compared to wild-type
FVB mice, leaving less residual infection (Fig 1D). Histological anal-
ysis indicated that LL-37 transgenic mice lung tissue displayed allevi-
ated alveolar tissue damage at 6 h after PAO1 infection, potentially
due to reduced bacterial burden (Fig 1D–F). Furthermore, the mRNA
levels of major pro-inflammatory cytokines including IL-6 and IL-1b
decreased in the lungs of LL-37 transgenic mice (Fig 1G).
To further characterize the LL-37 transgenic mouse lung before
and after bacterial infection, we performed RNA-Seq on lung tissues
to analyze their whole transcriptomic profiles. As expected, FVB
lungs had distinct transcriptomic profiles before and after PAO1
infection (PCC = 0.672). In contrast, LL-37+/+ lungs shared highly
similar whole transcriptomic profiles before and after PAO1 infec-
tion (PCC = 0.977), suggesting that the LL-37+/+ lungs were
protected from PAO1 challenge-induced alterations (Fig 2A). Inter-
estingly, we found that overexpression of LL-37 gave rise to upregu-
lation of multiple immune response-related genes even prior to
infection (Fig 2B). Further analysis on gene ontology revealed that
LL-37 expression enhanced normal mice development, including
muscle, and blood circulation, and augmented mucosal immune
response and organ-specific immune responses (Fig 2C). This
finding indicated that LL-37 could stimulate lung immunity to
protect infection, which was consistent with previous reports on
other cathelicidin or cathelicidin-related peptides (Kovach et al,
2012; Beaumont et al, 2014).
Next, we analyzed the lung transcriptomic profiles after PAO1
infection. The infected FVB mouse lungs were characterized by
elevated infection and immune-related processes, such as “defense
response” and “leukocyte activation”; in contrast, the infected LL-
37+/+ lungs were characterized by lung tissue homeostasis/devel-
opment-related processes, such as “lung epithelium development,”
“respiratory system development,” and “cilium” (Fig 2D and
Table EV1). Protein–protein interaction network analysis of overex-
pressed genes identified an inflammation-related molecular network
in infected WT lungs, and in contrast, a lung development-related
molecular network in infected LL-37+/+ lungs (Fig 2E). These data
indicate that constitutive LL-37 expression in mouse lung can
protect the lung from bacterial infection and inflammation.
Genetically engineered mDASCs express functional LL-37 peptide
LL-37 aids bacterial clearance in the mouse lung. We next deter-
mined if this peptide could be used in combination with DASCs to
protect damaged lung from infection. P63+/Krt5+ DASCs (mDASCs)
were isolated from normal adult mouse lung and expanded on 3T3
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feeder cells as stem cell clones. The LL-37 gene was introduced into
mDASCs by lentiviral transduction. Constitutive LL-37 expression
was detected at both RNA and protein levels in LL-37-mDASCs but
not in their wild-type counterpart (Fig 3A–C). WT-mDASCs and LL-
37-mDASCs expressed similar levels of stem cell markers P63 and
Krt5 (Fig 3D). mDASCs, irrespective of types, were able to be
passaged indefinitely in our system. Elevated LL-37 expression was
previously reported to affect cell viability and proliferation (Heil-
born et al, 2005), while in this study we did not detect significant
differences in either proliferation rate (Fig EV1A) or clonogenic abil-
ity (Fig 3E). In a three-dimensional organoid culture system, both
mDASC cell lines formed alveolar-like sphere structures consisting
of differentiated cells expressing AQP5 and PDPN, type I alveolar
cell markers (Fig 3F). To confirm that genetically modified mDASCs
were not tumorigenic, we assessed the anchorage-independent
growth potential of these cells. mDASCs after LL-37 lentiviral trans-
duction were unable to grow in soft agar medium, while mouse
melanoma cells (B16) exhibited robust colony-forming efficiency
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Figure 1. Constitutive expression of LL-37 protected mouse lung from bacterial infection.
A The schematic of human LL-37(CAMP) transgenic mouse strain.
B LL-37(4-kD) detection by Western blotting. Prior to loading, samples were centrifuged through 10-kD ultrafiltration membranes and an equal amount of ultrafiltrate
(19 lg/lane) was subjected to immunoblotting. High-molecular-weight proteins (GAPDH) were not detected in ultrafiltrate.
C The CFU of PAO1 was measured by culturing in ultrafiltrate (upper panel) or retentate (lower panel) of mouse BALF samples from indicated mice. Initial additions of
PAO1 were 1 × 103 CFU. Co-culture duration, 6 h. n = 3. Error bars, SEM.
D The bacterial CFU (per gram) in lungs of indicated mice with and without PAO1 infection (5 × 106 CFU). n = 3. Error bars, SEM.
E Representative histological sections of indicated lungs with PAO1 infection (5 × 106 CFU) for 6 h. H&E staining. Scale bar, 1,000 lm (upper panel) and 50 lm (lower
panel).
F Histopathological injury score of indicated mouse lungs with PAO1 infection (5 × 106 CFU) based on blinded expert judgment. n = 3. Error bars, SEM.
G Gene expression level of IL-1b and IL-6 of indicated mouse lung with PAO1 infection (5 × 106 CFU). n ≥ 3. Error bars, SEM.
Data information: Statistics for graphs: unpaired two-tailed t-test (C) and two-way ANOVA followed by Sidak’s test (D, F, G). *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001.
Source data are available online for this figure.
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under identical conditions (Fig EV1B). This indicated the successful
generation of a LL-37-expressing mDASC cell line with unaltered
self-renewal and differentiation properties.
To test whether functional LL-37 peptide could be produced
and secreted by LL-37-mDASCs, we assessed the bacterial clear-
ance ability of their culture-conditioned medium (CM). PAO1
growth was significantly inhibited by the CM from LL-37-mDASCs
but not from WT-mDASCs (Fig EV1C). In a series of cell/bacteria
co-culture assays, LL-37-mDASCs, when compared to WT-
mDASCs, showed impaired bacterial growth of PAO1 at different
infection doses and time points, although substantial bacterial
proliferation was observed under both conditions (Fig 3G–I). A
similar bacterial growth inhibitory effect of LL-37-mDASCs was
also detected with Gram-negative pathogen, Escherichia coli
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Figure 2. The altered transcriptomic profiles of transgenic mouse lungs before and after PAO1 infection.
A Heatmap showing transcriptome profile correlation values of indicated lung tissue samples before and after PAO1 infection.
B Histogram of selected differentially expressed genes of LL-37+/+ mouse lung versus wild-type FVB mouse lung prior to infection. Blue bars indicated genes
upregulated in wild-type FVB mouse lungs, while red bars indicated genes upregulated in LL-37+/+ mouse lungs.
C, D Enriched Gene Ontology classes of uninfected (C) and PAO1-infected (D) lungs. Red bar, GO class of upregulated gene in LL-37+/+ mice. Blue bar, GO class of
upregulated gene in wild-type FVB mouse lung. GO terms were ranked by the enrichment P-value.
E Protein–protein interaction network of selected genes with high expression level in PAO1-infected wild-type lung (blue) and PAO1-infected LL-37+/+ lung (red),
respectively.
Source data are available online for this figure.
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Figure 3. Engineered mDASCs possessed normal stem cell properties and enhanced antimicrobial potency.
A–C Detection of LL-37 expression in the engineered mDASCs by immunofluorescence (A), real-time quantitative PCR (B), and Western blot (C). Scale bar, 50 lm. BF,
bright field. n = 10. Error bars, SEM.
D Anti-Krt5 (red) and anti-P63 (green) immunostaining of WT- and LL-37-mDASC colonies. Scale bar, 70 lm.
E Stem cell colony-forming efficiency of WT- and LL-37-mDASCs during five serial passages. n = 6. Error bars, SD.
F Representative 3D organoid culture of mDASCs with expression of type I alveolar cell markers (Aqp5 and Pdpn). Left panels, bright-field imaging of 3D organoids.
Right panels, immunofluorescence of organoid sections. Scale bar, 20 lm.
G Co-culture of bacteria with DASCs shows antimicrobial effects in dose-dependent manner. Initial additions of PAO1 were 0.1 × , 0.5 × and 1 × 104 CFU,
respectively. Co-culture duration, 6 h. n = 4. Error bars, SEM. MOI, multiplicity of infection.
H Co-culture of bacteria with DASCs shows antimicrobial effects in time-dependent manner. Initial concentration of PAO1 was 1 × 104 CFU. MOI = 1. n = 3. Error
bars, SEM.
I, J Preincubation of cells with anti-LL-37 antibody, but not IgG control, significantly reduced anti-PAO1 (I) and anti-Escherichia coli (J) effects of LL-37-mDASCs. Initial
dose of bacteria was 103 CFU. Co-culture duration, 18 h. n = 4 in (I) and n = 3 in (J). Error bars, SEM.
Data information: Statistics for graphs: unpaired two-tailed t-test (B), two-way ANOVA followed by Sidak’s test (G, H) and one-way ANOVA followed by Tukey’s test (I, J).
*P < 0.05; **P < 0.01; ****P < 0.0001.
Source data are available online for this figure.
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(Figs 3J and EV1D and E). To confirm that the inhibitory effect of
engineered cells was attributed to LL-37 peptide production, we
used anti-LL-37 antibody to neutralize the secreted peptide.
Compared with IgG control, anti-LL-37 antibody compromised the
inhibitory effect of LL-37-mDASCs (Fig 3I and J) and their cellular
CM (Fig EV1F). Collectively, the above data demonstrate success-
ful engineering of LL-37-mDASCs with normal stem cell properties
and antimicrobial functions.
Regeneration of LL-37-Lung by transplantation of genetically
engineered mDASCs
To investigate the potential therapeutic effect of engineered DASCs
in vivo, we transplanted the LL-37-mDASCs into the damaged lung
of syngeneic animals. The chemotherapeutic drug bleomycin was
intratracheally instilled into the mouse lung to induce acute
pulmonary inflammation and alveolar tissue damage. Seven days
after bleomycin administration, 106 GFP-labeled WT-mDASCs or
LL-37-mDASCs were intratracheally delivered into injured mouse
lungs. We named the lungs with WT-mDASCs or LL-37-mDASCs
engraftment as WT-Lung or LL-37-Lung, respectively. The lung
tissues were harvested for analysis on different days after trans-
plantation. Substantial incorporation of mDASCs into mouse lung
was detected without observing significant rejection of cells
(Fig 4A). An equal engraft ratio was observed for the two cell
types, which both peaked around 21 days after transplantation and
remained stable thereafter (Fig 4B). Tissue sectioning and analysis
showed a broad distribution of stem cells and their progeny in
mouse lung parenchyma with a substantial proportion differenti-
ated into air sac-like structures with type I alveolar cell marker
AQP5 co-staining (Figs 4C and EV2A). A population of trans-
planted engineered cells continued to express the proliferation
marker Ki67 up to 28 days after transplantation (Fig 4D), suggest-
ing their high viability and extended contribution to the tissue
regeneration process.
For the LL-37-mDASC group, constitutive LL-37 expression was
specifically detected in the lung area with GFP+ stem cell incorpora-
tion (Figs 5A and EV2B). Importantly, there was no incorporation of
GFP+ stem cells in the uninjured lung (Fig EV2C), indicating speci-
fic targeting of LL-37 toward injured but not healthy lung tissue.
Regenerated LL-37-Lung has enhanced bacterial clearance ability
Previously, the capacity of LL-37 to enhance pulmonary bacterial
clearance 6 and 24 h post-PAO1 infection has been demonstrated
(Beaumont et al, 2014). To assess whether the LL-37-Lung had
enhanced host defense post-bacterial infection, WT-Lung and LL-37-
Lung were challenged with intratracheal delivery of PAO1
(Fig EV2D). The PAO1 load levels in mouse lung were quantified by
bacterial culture 6, 24, and 48 h after infection. LL-37-Lung had
significantly less PAO1 load in the whole lung homogenate (Fig 5B)
as well as in BALF (Fig 5C). A similar effect was observed when the
lungs were challenged with E. coli (Fig EV2E) 48 h after infection.
Correspondingly, differentially expressed genes measured by RNA-
Seq between infected WT-Lungs and LL-37-Lungs indicated that
LL-37 expression alleviated the inflammation reaction and downreg-
ulated the related pro-inflammatory pathways (Fig 5D and E).
Consequently, 2 days after infection, the mice with LL-37-Lung
demonstrated healthier pulmonary function, as shown by the higher
O2 partial pressure and O2 saturation, yet lower CO2 partial pressure
in arterial blood (Figs 5F and EV2F). Altogether, the data above
showed that the LL-37-expressing mDASC engraftment could protect
mouse lung from bacterial infection and improve the pulmonary
function of infected recipients.
Two days after infection, we investigated the effects of LL-37-
mDASCs on histopathological changes in lung injury (Fig 6A and B
for PAO1 infection and Fig EV2G for E. coli infection). Intratracheal
bleomycin administration caused acute alveolar damage and
inflammation aggravated by bacterial infection. However, the
destructive changes to the lung were significantly attenuated by LL-
37-mDASCs and lung injury scores were significantly decreased,
compared to the WT-mDASC treated mice. Levels of CD68 protein, a
marker for macrophages, were also examined by immunohisto-
chemistry (Fig 6C and D). The data showed an increase of CD68
expression in lung tissues following bleomycin + PAO1 treatment,
which was significantly alleviated by treatment with LL-37-
mDASCs. Real time qPCR analysis of major pro-inflammatory
cytokines including IL-1b, TNF-a, and IL-6 showed a less severe
inflammatory response in the LL-37-Lung after infection (Fig 6E).
LL-37-expressing human DASC engraftment protects
bioengineered artificial lung from bacterial infection
Following on from our demonstration that DASCs can be success-
fully engrafted into native lung, we next assessed engraftment into a
bioengineered artificial lung. Bioengineered artificial lungs are a
highly promising alternative organ source for clinical lung trans-
plant surgery, given that suitable, autologous source seed cells are
used to reconstruct functional epithelium and avoid immune rejec-
tion (Petersen et al, 2010). Furthermore, infection before and after
organ transplant surgery is a major hindrance to successful organ
transplants, and development of an anti-infective bioengineered
organ may provide a functional alternative.
To test the feasibility of artificial lung construction with human
DASCs (hDASCs), we isolated adult hDASCs from the sixth-order
airway of bronchiectasis patients by bronchoscopic brushing
followed by large-scale cell expansion on irradiated 3T3-J2 feeder
cells (Hackett et al, 2011; Ma et al, 2018; Fig 7A). The LL-37
expression level in wild-type hDASCs was barely detectable. A
lentiviral system was used to stably overexpress LL-37 up to a
thousand-fold (Figs 7B, and EV3A and B). We expanded the engi-
neered hDASCs as homogeneous, immature clones to indefinite
numbers in vitro and achieved approximately 100 million cells in
< 3 weeks.
To construct bioengineered artificial lungs, we harvested rat
lungs and decellularized them by airway perfusion, as previously
reported (Gilpin et al, 2016). Complete removal of cellular compo-
nents and proper preservation of extracellular matrix were demon-
strated by morphologic and cell nucleus analyses (Figs 7C and
EV3C). GFP-labeled WT- and LL-37-hDASCs were then delivered
into the lung through the trachea by gravity to repopulate the scaf-
fold and maintained the recellularized lung in ex vivo biomimetic
culture for 7 days (Fig 7D). Large-scale cellular engraftment was
detected by direct GFP fluorescence observation (Fig 7E).
Immunofluorescence staining showed that most cells preserved the
KRT5+ hDASC phenotype (Fig EV3D). However, we found that a
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few grafted cells acquired an elongated shape with AQP5 marker
expression, suggesting the gradual maturation of these stem cells
into type I alveolar cells (Fig EV3E).
Substantial LL-37 expression was detectable in LL-37-hDASC
recellularized lungs (Fig 7F). Successfully recellularized lungs were
co-cultured with PAO1 or E. coli to examine their inhibiting growth
ability. The results showed, compared to wild-type ones, that the
LL-37-hDASC recellularized lungs had improved bacterial clearance
ability (Fig 7G). Collectively, the above work proposes a novel
genetic and stem cell-based therapeutic strategy for the treatment of
recurrent, antibiotic-resistant pulmonary infections.
Discussion
Here, we have demonstrated that constitutive expression of LL-37
peptide can protect the lung from bacterial infection, and transplan-
tation of LL-37-expressing DASCs can be used to regenerate lung
A
B
D
C
Figure 4. Lung engraftment of WT- and LL-37-mDASCs after orthotopic transplantation.
A Bright-field and direct fluorescence images of mouse lungs following transplantation of 1 × 106 GFP-labeled WT-mDASCs (WT-Lung) or LL-37-mDASCs (LL-37-Lung)
on indicated days. Scale bar, 1,000 lm.
B Engraftment ratio of indicated cells in mouse lungs on indicated days. n = 3. Error bars, SEM. *P = 0.0474. Statistics: two-way RM ANOVA followed by Tukey’s test.
C Morphology of engrafted GFP-labeled cells in lung parenchyma by direct fluorescence. Blue color indicates nucleus DAPI staining. Scale bar, 200 lm.
D Anti-Ki67 immunofluorescence of engrafted GFP-labeled WT- and LL-37-mDASCs in lung parenchyma 21 days after transplantation. Scale bar, 50 lm.
Source data are available online for this figure.
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with enhanced host defense capability. Considering that respiratory
infection has become the leading reason for human death and the
number of antibiotic-resistant cases is constantly increasing
(Theuretzbacher & Toney, 2006), the concept of host defense
augmentation is an attractive approach with great clinical potential
(Finlay & Hancock, 2004; Spellberg et al, 2004; Easton et al, 2009).
LL-37 plays a key role in inhibiting the formation of P. aeruginosa
biofilm at lower concentrations and directly degrades biofilms at
higher concentrations (Dean et al, 2011). Moreover, the anti-infec-
tion mechanism of LL-37 in vivo is likely to be more complex than
simple direct microbicidal effects. Systematic administration of LL-
37 protects mice from pulmonary bacterial infection (Beaumont
et al, 2014), and transfer of LL-37 restored bacterial killing in a cystic
fibrosis xenograft model (Bals et al, 1999a). Systemic expression of
A
B D
C
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Figure 5. LL-37-expressing lung had enhanced host defense ability.
A Distribution of engrafted GFP-labeled cells in lung parenchyma by immunofluorescence 7 days after transplantation. WT-Lung, WT-mDASCs engrafted; LL-37-Lung,
LL-37-mDASCs engrafted. Scale bar, 200 lm. Arrows show the representative cells with overlapping fluorescence of GFP and LL-37.
B Intratracheal instillation of equal amount of PAO1(5 × 106 CFU per mouse) into WT-Lung (WT-mDASCs engrafted) and LL-37-Lung (LL-37-mDASCs engrafted) followed
by bacterial CFU analysis in whole lung homogenates 6, 24, and 48 h after infection. n = 3. Error bars, SEM.
C Intratracheal instillation of equal amount of PAO1 into WT-Lung and LL-37-Lung followed by bacterial CFU analysis in BALF 6, 24, and 48 h after infection. n = 3.
Error bars, SEM.
D Downregulated gene in LL-37-Lung enriched in Gene Ontology and KEGG pathways.
E Protein–protein interaction network of selected genes with high expression level in WT-Lung (red) and LL-37-Lung (blue), respectively.
F Arterial blood gas analysis of mice with WT-Lung and LL-37-Lung following PAO1 infection. n = 6. Error bars, SEM.
Data information: Statistics for graphs: two-way ANOVA followed by Sidak’s test (B, C) and unpaired two-tailed t-test (F). *P < 0.05; **P < 0.01; ****P < 0.0001.
Source data are available online for this figure.
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LL-37/hCAP-18 after intravenous injection also resulted in improved
survival rates following intravenous injection of lipopolysaccharide
with galactosamine or E. coli (Bals et al, 1999b).
Wild-type mice challenged with P. aeruginosa, pro-inflammatory
cytokines, and chemokines, including Il-6, Il-1, and Cxcl1, were
significantly recruited. Yet, infection and inflammation of LL-37+/+
mice were reduced, as confirmed by transcriptomic analysis. Both
Wnt and FGF signals, recognized as key factors in pulmonary devel-
opment and regeneration (Shu et al, 2005; Zacharias et al, 2018),
were also activated in infected LL-37+/+ mice. We used DASCs as a
vehicle for LL-37 antimicrobial peptide to achieve improved deliv-
ery. The incorporated DASCs itself could rapidly establish the
epithelium barrier, which seems to have protective effects on
pulmonary infection, while LL-37-DASCs have even stronger protec-
tive effects than WT-DASC. As DASCs will not incorporate into
healthy pulmonary tissue or other tissues or organs, our current
strategy ensured the localized distribution of LL-37-DASCs to
injured lung foci, where they can concentrate to combat local
pulmonary infection with little or no side-effects on other healthy
tissue or organs. Meanwhile, LL-37-DASCs avoid limitations such as
fast degradation following direct application of synthetic LL-37. At
the same time, we have shown that overexpression of LL-37 impacts
neither the viability of host cells nor the general health of LL-37
transgenic mice. All the above data show the evidence that LL-37-
DASCs provide a promising therapeutic exploration for lung infec-
tion. However, the potential risk associated with longer-term release
of LL-37 in vivo needs to be fully investigated as well.
We also used LL-37-hDASCs to recellularize lung scaffolds and
successfully established an anti-infective bioengineered lung. It
should be noted that the bioengineered lung built in the current
work is only conceptual and could not contribute to recipient
pulmonary function, even if transplanted, due to lack of proper
vasculature. However, it demonstrated an important proof of
concept, namely, that patient-specific DASCs could be isolated and
genetically engineered to build artificial organs with demanding
biological functions.
A B
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Figure 6. LL-37-mDASCs transplantation protected infected mouse from pulmonary inflammation.
A H&E staining showing histology of injured lung infected by PAO1 with WT-mDASCs or LL-37-mDASCs transplantation. Scale bar, 100 lm.
B Histopathological examination according to the lung injury scoring system based on blinded expert judgment. n = 5 mice per group. Error bars, SEM.
C CD68 immunochemistry (brown) in infected lung with WT-mDASCs or LL-37-mDASCs transplantation. Scale bar, 50 lm.
D Quantification of brown-stained (CD68+) area by Image J software. n = 5. Error bars, SEM.
E Gene expression level of indicated pro-inflammatory cytokines of lung infected by PAO1 with WT-mDASCs or LL-37-mDASCs transplantation. n = 3. Error bars, SEM.
Data information: Statistics for graphs: one-way ANOVA followed by Tukey’s test. **P < 0.01; ***P < 0.001; ****P < 0.0001.
Source data are available online for this figure.
ª 2019 The Authors EMBO Molecular Medicine e10233 | 2019 9 of 16
Yue-qing Zhou et al EMBO Molecular Medicine
AC
E
G
F
D
B
Figure 7. Lung scaffold recellularized by LL-37 engineered human DASCs has enhanced anti-bacterial ability.
A Anti-Krt5 (red) and anti-P63 (green) immunofluorescence of isolated hDASCs. Scale bar, 90 lm.
B The mRNA expression levels of LL-37 were measured by real-time qPCR for WT- and LL-37-hDASCs. n = 5. Error bars, SEM.
C H&E staining of native rat lung tissue and decellularized scaffold showed the absence of nuclei following decellularization. Scale bar, 40 lm.
D Ex vivo biomimetic culture of LL-37-hDASCs recellularized lungs with constant media perfusion.
E Direct fluorescence image showing GFP-labeled LL-37-hDASCs before (left) and 7 days after (right) being engrafted onto the decellularized scaffold. Scale bar, 50 lm
(right panel) and 2,000 lm (right panel).
F Immunofluorescence of recellularized lung with indicated antibodies. Blue color indicates nuclear DAPI staining. Scale bar, 50 lm.
G The recellularized lung by LL-37-hDASCs displayed growth inhibitory effect on PAO1 and Escherichia coli. Initial dose of bacteria was 2 × 104 CFU. Culture duration,
24 h. n = 6. Error bars, SEM.
Data information: Statistics for graphs: unpaired two-tailed t-test (B) and one-way ANOVA followed by Tukey’s test (G). *P < 0.05; ***P < 0.001; ****P < 0.0001.
Source data are available online for this figure.
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In addition to DASCs, many other distinct populations of adult
lung stem/progenitor cells have been reported to exert regenerative
functions under different circumstances (Barkauskas et al, 2013;
Leeman et al, 2014; Nabhan et al, 2018). Among them, only DASCs
were tested in the current study, as such cells were easily expanded,
genetically manipulated, and transplanted into the damaged lung. We
did observe a fraction of transplanted LL-37-DASCs differentiating
into mature alveolar cells in vivo. However, even undifferentiated,
the engrafted LL-37-DASCs could rapidly establish an epithelial
barrier to prevent the spread of bacteria and inflammation while
maintaining the local antimicrobial peptide concentration. Once the
bacteria were gradually cleared by LL-37 and other immune factors,
the improved microenvironment could further accelerate LL-37-DASC
maturation process. We anticipate that similar genetic engineering
strategies can also be applied to other lung stem/progenitor cell
types—including but not limited to type II alveolar cells—that might
exert synergistic effects on lung repair following transplantation.
In clinical practice, genetically engineered cells are being recog-
nized as powerful “living drugs” for treating many previously
uncured diseases. For example, substantial advances have been
made in the field of T-cell-mediated cancer therapy. Based on this
technique, T cells are genetically modified by viral vector transduc-
tion that either alter T-cell receptor (TCR) specificity or introduce
antibody-like recognition into chimeric antigen receptors (CARs)
(Sadelain et al, 2017). The successful application of genetically engi-
neered T cells is encouraging the field to develop more gene- and
cell-based therapies. As LL-37 peptide has already demonstrated
safety and efficacy in human infectious disease treatment (Gronberg
et al, 2014) and human DASC transplantation was also previously
tested in a pilot clinical trial (Ma et al, 2018), we think their combi-
nation could lead to a promising practical therapy with great clinical
potential for those life-threatening lung infections.
Materials and Methods
Animals and bacteria
Female C57/B6 mice and wild-type FVB mice (6–8 weeks) weighing
16–18 g were purchased from Shanghai SLAC Laboratory Animal
Co., Ltd. (China). LL-37+/+ mice (Fvb background) were produced
by Cyagen Biosciences Inc. (China). Male Sprague-Dawley rats,
weighing 180–220 g each were purchased from Shanghai SLAC
Laboratory Animal Co., Ltd. (China). All mice were housed in speci-
fic pathogen-free conditions within an animal care facility (Center of
Laboratory Animal, Tongji University, Shanghai, China) until eutha-
nization. All animals were cared for in accordance with NIH guideli-
nes, and all animal experiments were performed under the guidance
of, and with approval from, the Institutional Animal Care and Use
Committee of Tongji University. Pseudomonas aeruginosa (ATCC-
BAA-47; strain HER-1018/PAO1) and E. coli strain DH5-a (ATCC-
98489) were used in these experiments.
Generation of LL-37+/+ transgenic mice
All animal experiments were performed according to guidelines
approved by the Tongji University Association for Laboratory
Animal Science. To understand whether the expression of LL-37 is
beneficial in vivo, we constructed a transgenic mouse that expressed
the human CAMP gene. To begin with, we constructed the LL-
37-expressing plasmid. Full-length human CAMP cDNA (NCBI:
NM_004345.4) was inserted into an IRES vector with a GFP expres-
sion sequence under a constitutively active EF-1a promoter. Next,
fertilized eggs obtained from FVB background mice were injected
with the pIRES human LL-37 expression plasmid described above
and then implanted into FVB females to generate LL-37 founders.
Then LL-37+/+ mice were identified using genotyping PCR for LL-
37 gene expression, which was performed on tails that were
obtained from mice aged 3–4 weeks old. PCR was performed using
the following primers: LL-37 F: 50-AGCAGTCACCAGAGGATTGT-30
and LL-37 R: 50-GGCACACACTAGGACTCTGT-30. The PCR product
produced by LL-37+/+ mice was 135 bp long. LL-37 protein expres-
sion was analyzed using Western blotting analysis. PCR-negative
littermates and wild-type (FVB) mice were used as controls.
Tissue histology and immunohistochemistry
For mouse lung histology analysis, mice were euthanized and the
diaphragm was carefully cut to open without touching the lung.
Lung was inflated with 3.7% formaldehyde (Sigma, USA) using a
30G needle through trachea. Then the lung was dissected and fixed
in 3.7% formaldehyde at 4°C overnight before paraffin section or
cryosection.
For cryosection, the fixed lung was settled by 30% sucrose before
embedding into the Tissue-Tek O.C.T compound (Sakura, Japan),
solidified on dry ice, and cut using cryotome (Leica Microsystems,
Germany) into 5- to 10-lm thickness. For paraffin section, the lung
was dehydrated by gradient ethanol in an automatic tissue processer
and then embedded into paraffin blocks. The blocks were cut into 5-
to 7-lm thickness by using microtome (Leica Microsystems,
Germany) at distinct planes. The sections were placed on polylysine
coated glass slides and stored at room temperature until further use.
Hematoxylin and eosin (H&E) staining was performed following
standard protocol. The lung injury score was calculated as previ-
ously described (Matute-Bello et al, 2011). For immunostainings,
sections were deparaffinized, rehydrated, and blocked by 0.3%
H2O2 for 30 min. Antigen retrieval was performed by treating the
slides in citrate buffer in a microwave oven for 10 min. The slides
were incubated for 1 h with normal goat serum, and then incubated
in a moist chamber with anti-CD68 (ab125212, Abcam) antibody at
4°C overnight. After a complete wash in phosphate-buffered saline
(PBS), the tissues were incubated in biotin-labeled goat anti-mouse
antibody for 30 min and rinsed with PBS, and incubated with
avidin–biotin–peroxidase complex for 30 min at 37°C. The signal
was detected using diaminobenzidine (DAB). Brown-stained area
(CD68+ cells in the monocyte lineage) was separately quantified by
Image J version 1.52a.
Immunofluorescence
For immunofluorescence staining, cells or tissues were fixed by
3.7% formaldehyde, and then incubated with 0.2% Triton X-100 to
improving the cell permeability for 10 min. Paraffin- or cryo-
embedded tissues were sectioned and subjected to antigen retrieval
in citrate buffer (pH 6.0, Sigma, USA) in microwave oven for
20 min before staining. Normal donkey serum at 10% concentration
ª 2019 The Authors EMBO Molecular Medicine e10233 | 2019 11 of 16
Yue-qing Zhou et al EMBO Molecular Medicine
(Jackson Immuno Research) was used to block the non-specific anti-
gen. Primary antibodies used in this work include DASC markers:
KRT5 (1:200, EP1601Y, Thermo and ab128190, Abcam); P63
(deltaN,1:200, 4A4, Abcam); pneumocyte markers like AQP5
(1:200, EPR3747, Abcam); and others like GFP (1:200, B-2, Santa
Cruz), GFP (1:1,000, ab5450, Abcam), GFP (1:1,000, ab290,
Abcam), and LL-37/cathelicidin (1:200, ab69484 and ab80895,
Abcam). Alexa Fluor-conjugated Donkey 488/594 (1:200, Life Tech-
nologies, USA) was used as secondary antibodies. After counter-
staining with DAPI (Roche, USA), samples were treated with 0.1%
Sudan Black (Sigma, USA) for 1–2 min to remove autofluorescence
and then mounted with VECTASHIELD Mounting medium (Vector
labs, USA). Stained slides were stored at 4°C in the dark and images
were taken using fluorescence microscope (Nikon 80i and Eclipse
Ti, Nikon, Japan).
RNA sequencing analysis and bioinformatics
For RNA sequencing, lungs were dissected in ice-cold phosphate-
buffered saline and lungs from FVB/LL-37+/+ or GFP+ lobe from
WT-Lung/LL-37-Lung were dedicated for RNA isolation. Total RNA
was extracted using TRIzol Reagent (Invitrogen, LifeTechnologies,
USA) following the manufacturer’s instructions, and then treated
with DNase I (Invitrogen, Life Technologies, USA). The RNA integ-
rity was verified using an Agilent 2100 BioAnalyzer (Agilent, USA).
The cDNA library construction and sequencing were performed
using BGISEQ-500 platform. High-quality reads were aligned to the
mouse reference genome (UCSCmm10) using Bowtie2 (v2.2.5). The
expression levels for each of the genes were normalized to frag-
ments per kilobase of exon model per million mapped reads (FPKM)
using RNA-Seq by Expectation Maximization (RSEM) (v1.2.12), and
the common genes among samples were displayed by Venn Charts.
NOISeq method was used to screen differentially expressed genes.
Cluster and java Treeview were used to perform clustering analysis
of the DEGs. The threshold for significant differential expression
was based on the Poisson distribution (Fold Change ≥ 2.00 and
FDR ≤ 0.001). Using the cor function in R, we calculated the Pear-
son correlation coefficient (PCC) between each of the two samples.
Gene Ontology (GO) enrichment analysis of differentially expressed
genes was implemented by the phyper function in R. With the KEGG
annotation result, we classified DEGs according to official classifi-
cation, and we also performed pathway functional enrichment using
phyper, a function of R. We used DIAMOND (Buchfink et al, 2015)
to map the DEGs onto the STRING (von Mering et al, 2005) data-
base to obtain the interaction between DEG-encoded proteins using
homology with known proteins. For the entire interaction result, we
provided an input file that could be imported directly into Cytoscape
for network analysis.
Isolation and culture of mouse and human DASCs
Mouse DASC cells were isolated and cultured as previously
described (Zuo et al, 2015). Briefly, lung tissue was collected from
adult mice and immersed in cold wash buffer (F12 medium, 1%
Pen/Strep, 5% FBS). The main bronchi were removed from the
lungs and the lobes were cut with sterile surgical blade into small
pieces and digested with dissociation buffer (F12/DMEM, 1 mg/ml
protease, 0.005% trypsin, and 10 ng/ml DNaseI) over night with
gentle rocking. Dissociated cells were passed through 70-lm nylon
mesh and then washed twice with cold F12 medium.
To isolate human DASCs, bronchoscopy procedure for lung
sampling was performed by board-certified respiratory physicians
using a flexible fiber-optic bronchoscope (Olympus, Japan). Before
bronchoscopy, oropharyngeal and laryngeal anesthesia was
obtained by administration of 2 ml of nebulized 4% lidocaine,
followed by 1 ml of 2% topical lidocaine sprayed into the patient’s
oral and nasal cavities. After the bronchoscope was advanced
through the vocal cords, 2 ml of 2% lidocaine solution was instilled
into the trachea and both main bronchi through the working chan-
nel of the bronchoscope. Then a disposable 2-mm brush was
advanced through the working channel of the bronchoscope and
used to collect airway epithelial cells by gently gliding the brush
back and forth two times in 4–6 order bronchi in the right or left
lobe. To isolate the human DASCs, the brush with samples were cut
with scissors into 1-cm pieces. After removing sputum, the brush
pieces were directly digested with dissociation buffer described
above. Specimens were incubated at 37°C for an hour with gentle
rocking. Dissociated cells were passed through 70-lm nylon mesh
and then washed twice with cold F12 medium. All the human
tissues were obtained following clinical SOP under patient’s consent
and approved by Shanghai East Hospital Ethics Committee (Shang-
hai, China). Informed consent was obtained from all subjects and
all the experiments conformed to the principles set out in the WMA
Declaration of Helsinki and the Department of Health and Human
Services Belmont Report.
Mouse or human cells were then plated onto feeder cells in DASC
culture medium including DMEM/F12, 10% FBS (Hyclone,
Australia), Pen/Strep, amphotericin, and growth factor cocktail as
previously described. Under 7.5% CO2 culture condition, the DASC
colonies emerged 3–5 days after plating, and were digested with
0.25% trypsin-EDTA (Gibco, USA) for 3–5 min for passaging. Typi-
cally, DASCs are passaged every 5–7 days and split at 1:7 ratio.
For anchorage-independent growth assay, 1 × 105 cells were
seeded in 1 ml of a 0.375% upper agar (Sigma) layer on 0.5% under
agar layer in the DMEM supplemented with 10% FBS. Cultures were
usually maintained for 14 days, and then gels were stained by crys-
tal violet-methanol solution (Solarbio).
To express LL-37 in stem cells, full-length human CAMP cDNA
was cloned from human genome into pHIV-EGFP plasmid vector.
Then pHIV-CAMP-EGFP was used to generate lentiviral particles in
293T cells, which was transduced into DASC in combination of
10 lg/ml polybrene. pHIV-EGFP lentivirus was transduced for
control purpose. The cell viability of cells was assessed by MTT Cell
Proliferation and Cytotoxicity Assay Kit.
In vitro antimicrobial assay
Assessment of direct inhibition of bacterial growth by LL-37-DASC or
its conditioned medium (CM), which had been incubated with cells
for 24 h, was done by counting CFU. Cells or CM in 96-well plates (ap-
prox. 1 × 104 cells per well) within culture mediumwithout antibiotics
and FBS were pre-incubated with 1 lg/ml anti-LL-37 antibody
(HM2070, Hycult biotech) or mouse isotype antibody control
(B30010M, Abmart) for 2 h, and then co-cultured with P. aeruginosa
or E. coli in a humidified CO2 incubator. Aliquots of culture medium
were taken from each well and serially diluted with sterile PBS. Then
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they were brought onto a solid medium and evenly spread over the
LB-agar surface. After incubation, the number of colonies present on
the agar surface was counted, and the number of CFU in the sample
was then calculated. For BALF antimicrobial assay, 0.5 ml BALF/per
mouse was collected using standard protocol and then processed by
Ultra-4 10K Centrifugal Filter Device (Amicon, Millipore) at 4,000 × g
for 60 min at 4°C to collect the ultrafiltrate and retentate. About 1 ml
of ultrafiltrate or retentate was diluted with equal volume of LB
medium and used for 6-h bacterial suspension culture, followed by
overnight agar culture and CFU counting.
3D organoid culture of DASC
Three-dimensuional organoid culture of mouse DASCs was
performed on Matrigel matrix (Corning, USA) as previously
described. Cells were first cultured in culture medium for 2 days
and then transferred to serum-free DMEM/F12 medium supple-
mented with FGF10 (50 ng/ml, Peprotech, USA), Transferrin (5 lg/
ml, Peprotech, USA), HGF (20 ng/ml, Peprotech, USA), and 5%
BSA for 5 days to induce distal lung differentiation. After sphere
formation and differentiation, the organoids were harvested, embed-
ded in Tissue-Tek O.C.T. Compound (Sakura, USA), and frozen in
dry ice and ethanol mixture. For analysis, 5-lm sections were
obtained and subjected to immunofluorescence for the indicated
mature pulmonary markers, followed by counterstaining with DAPI.
DASC transplantation
Mouse lung was injured by intratracheally instilling with 3 U/kg
body weight of bleomycin (Selleckchem, USA) 7 days prior to
transplantation. Then mice were anesthetized by isoflurane and
rested on a stand. One million GFP-labeled DASCs were
suspended in 50 ll of PBS and used for transplantation of each
mouse. Intratracheal aspiration was performed by injecting the
cells into trachea via mouth. Bright-field and direct fluorescence
images of the transplanted lung were acquired under the fluores-
cence stereomicroscope (MVX10, Olympus, Japan). Engraftment
ratio was then calculated by the area ratio of GFP fluorescence in
the lung tissue.
PAO1 and Escherichia coli infection mouse model
Pseudomonas aeruginosa (PAO1, ATCC 9027) and the E. coli strain
DH5-a were used to model lung infection in mice as previously
described (Torres et al, 2018). Bacterial concentrations were validated
by plating on LB-agar and counting colony-forming units (CFU).
Before each experiment, the bacterial samples were washed twice and
resuspended in PBS. Mice were anesthetized with isoflurane and
PAO1 or E. coli (5 × 106 CFUs) were intratracheally instilled into
mouse lung. To evaluate whether LL-37-mDASCs show enhanced host
defense in vivo, mice were treated with 3 U/kg body weight of bleo-
mycin (Selleckchem, USA) 7 days in advance and then they were
instilled with bacteria and mDASCs (1 × 106) in a 30 ll total volume.
Intratracheal aspiration was performed by instilling the bacteria and
cells into the trachea via mouth, which was described in previous
publications (Shi et al, 2019). Two days post-infection, mice were
sacrificed, and the lung samples and BALFs were collected for analy-
sis. To collect BALF, a 20-gauge catheter was placed into the mouse
trachea through which 1 ml of cold PBS was flushed back and forth
three times. Aliquots of BALF were diluted and cultured on LB-agar
plate for 16 h at 37°C before CFU counting. For lung homogenate
harvest, the pulmonary lobes with the stem cell incorporation were
separated under the stereomicroscope and then homogenized under
sterile conditions. Aliquots of homogenate were diluted and cultured
on LB-agar plate for 16 h at 37°C for CFU counting.
Arterial blood gas measurement
Mice were anesthetized and the blood samples were drawn from the
carotid aorta into polypropylene syringes containing 60 IU of dry,
electrolyte-balanced heparin (PICO70; Radiometer Medical, Copen-
hagen, Denmark). Partial oxygen pressure (pO2), partial carbon
dioxide pressure (pCO2), and oxygen saturation (sO2) were
measured by using ABL90 Flex Blood Gas Analyzer (Radiometer
Medical).
Decellularization and recellularization of the rat lung
Rat lungs were harvested from male Sprague-Dawley rats and
decellularized by perfusion of 0.1% SDS solution and 1% TritonX-
100 solution through the trachea at 15 rpm, followed by washing.
For recellularization, GFP-labeled WT-hDASCs and LL-37-hDASCs
(1 × 106) were delivered to rat lung scaffold, respectively, in
10 ml of media by gravity. Constant media perfusion of serum-free
DMEM/F12 medium supplemented with FGF10 (50 ng/ml; Pepro-
tech, USA), Transferrin (5 lg/ml; Peprotech, USA), HGF (20 ng/
ml; Peprotech, USA), 2% Matrigel, and 5% BSA through the
pulmonary artery was maintained at 4 ml/min and changed daily.
Recellularized lungs were maintained in culture for 7 days. For
antimicrobial assay, recellularized lung lobes were dissected and
co-cultured with PAO1 or E. coli (2 × 104 CFU) in 24-well plates
and incubated at 37°C for 24 h, while bacteria were cultured with
medium in the control group. Then aliquots of culture medium
were diluted and plated on LB-agar plates for bacterial colony
number counting.
Real-time qPCR
RNA was isolated from cells or tissue, using the RNeasy mini kit
with DNase digestion according to the manufacturer’s instructions
(Qiagen). RNA, the quality of which was assessed with SimpliNano
(GE Healthcare), was reverse-transcribed into cDNA with Prime-
ScriptTM RT Master Mix (TaKaRa). The Q-PCR was performed on an
ABI 7500 real-time PCR system (Applied Biosystems) under follow-
ing conditions: 95°C for 2 min, then 40 cycles of 95°C for 10 s, and
60°C for 40 s. The relative expression level of genes was calculated
using the 2DDCt method.
Primers: hCAP18/LL-37: F 50-CACAGCAGTCACCAGAGGATTG-30,
R 50-GGCCTGGTTGAGGGTCACT-30; Il-1b: F 50-CAACCAACAAGTGA
TATTCTCCATG-30, R 50-GATCCACACTCTCCAGCTGCA-30; Il-6: F 50-
GAGGATACCACTCCCAACAGACC-30, R 50-AAGTGCATCATCGTTGTT
CATACA-30; TNF-a: F 50-CATCTTCTCAAAATTCGAGTGACAA-30; R 50-
TGGGAGTAGACAAGGTACAACCC-30; b-actin: F 50-TACCACCATGT
ACCCAGGCA-30, R 50-CTCAGGAGGAGCAATGATCTTGAT-30; GAPDH:
F 50-CGGAGTCAACGGATTTGGTCGTAT-30, R 50-AGCCTTCTCCAT
GGTGGTGAAGAC-30.
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Western blotting
Cells or tissues were washed with cold PBS and lysed in RIPA buffer
(CST) containing protease inhibitors cocktail (Roche) followed by
standard Western blotting procedure. To detect the 4-kD LL-37
expression, tissue lysates were centrifuged through Ultra-4 10K
Centrifugal Filter Device (Amicon, Millipore) at 4,000 × g for 60 min
at 4°C to collect ultrafiltrate whose mass was less than 10-kD. After
measuring protein concentration, samples were loaded and sepa-
rated on 4–20% precast polyacrylamide gels, and then transferred to
PVDF membranes (Roche) at 100 V for 10 min. Membranes were
blocked with 5% no-fat powdered milk, and then incubated with
primary antibodies overnight, followed by secondary antibodies.
The specific signals were detected by Immobilon Western Chemilu-
minescent HRP Substrate (Millipore) and Tanon image system. The
following antibodies were used: LL-37/cathelicidin (Santa Cruz,
D-5), GAPDH (ab8245, Abcam), and HRP-conjugated anti-mouse IgG
(H+L) as secondary antibody (800151, Vazyme).
Statistics
All statistical analyses were performed using GraphPad Prism 7 soft-
ware. A significance threshold was set at P < 0.05. All experiments
were performed in three independent triplicates at least. P-values
are provided in Appendix Table S1. *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001.
Data availability
The RNA-Seq data are available at the Sequence Read Archive (SRA)
https://www.ncbi.nlm.nih.gov/sra (Accesion no. PRJNA559606 and
PRJNA559986).
Expanded View for this article is available online.
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